Adam Samuel Sperling, M.D.,Ph.D.
This page shows the publications co-authored by Adam Sperling and Max Jan.
Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021 Mar 02.
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021 Jan 06; 13(575).
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170.
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 09; 585(7824):293-297.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.